Skip to main content
An official website of the United States government
Español
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Xofigo

(SOH-fee-goh)
A radioactive drug used to treat prostate cancer that has spread to the bone and is causing symptoms but has not spread to other organs. It is used in patients whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). It is also being studied in the treatment of other types of cancer. Xofigo contains a radioactive substance called radium Ra 223. It collects in bone and gives off radiation that may kill cancer cells. Xofigo is a type of radiotherapeutic agent. Also called radium Ra 223-dichloride.
More Information
Search NCI's Dictionary of Cancer Terms